The Government of Cuba reported this Monday that its vaccine Abdala, a nationally manufactured anticovid drug, has demonstrated an efficacy of more than 90% in a three-dose scheme, according to the results presented by the Center for Genetic Engineering and Biotechnology (CIGB).
“Abdala reaches 92.28% efficiency with its three-dose scheme and becomes the second of the Cuban vaccine candidates that meet the requirements demanded by the World Health Organization (WHO) to become a vaccine,” said the account presidential office of that body on Twitter.
#Abdala | It reaches 92.28% efficiency with its 3-dose scheme and becomes the second of the #CandidatesVacunalesCubanos that meets the requirements of the @WHO to become a vaccine. @MINSAPCuba@BioCubaFarma@CIGBCuba | #CubaEsCiencia#Cuba🇨🇺 https://t.co/t4mIuqkHpK
– Presidency Cuba (@PresidenciaCuba) June 21, 2021
The Abdala vaccine was developed by the Center for Genetic Engineering and Biotechnology. It is based on the formulation of the RBD protein (Receptor Binding Domain), and uses aluminum hydrogen as an amplifier of the immune response.
The design of the drug uses RBD and the ACE 2 receptor, the main access route of the coronavirus to the cell that infects and causes disease in the individual.
It was recently known that another Cuban candidate against the coronavirus, the Sovereign 02, He showed 62% effective in its two-dose schedule.
Above all obstacles
Within the framework of this announcement, the president of Cuba, Miguel Díaz-Canel, highlighted that scientists from the Finlay Vaccine Institute and the Center for Genetic Engineering and Biotechnology “jumped over all obstacles,” including the pandemic and the blockade. economic against the island, to get “two very effective vaccines“.